Details of the Drug

General Information of Drug (ID: DM5Z3VP)

Drug Name
Ertumaxomab
Synonyms Rexomab; Rexomun; Trifunctional antibody (breast cancer), TRION/Fresenius; Trifunctional bispecific (CD3/Her2/neu) antibody (breast cancer), TRION/Fresenius
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 2 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D0O2JI

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Erbb2 tyrosine kinase receptor (HER2) TT6EO5L ERBB2_HUMAN Not Available [1]
T-cell surface glycoprotein CD3 epsilon (CD3E) TTZAT79 CD3E_HUMAN Not Available [1]
T-cell surface glycoprotein CD3 gamma (CD3G) TTV3XPL CD3G_HUMAN Not Available [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Breast cancer
ICD Disease Classification 2C60-2C65
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
T-cell surface glycoprotein CD3 epsilon (CD3E) DTT CD3E 1.53E-06 -0.93 -1.37
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.